Cantabio Pharmaceuticals $CTBO promoted on purported Alzheimer’s cure

A recent low-volume landing page pump and dump is of Cantabio Pharmaceuticals. See landing page here: http://biosciencereport.com/ctbo/main/ctv1.php

ctbo

Disclosed budget: $150,000 per week
Promoter:  Biosciencereport.com / KyIne Ltd
Paying party:  Ikon Media
Shares outstanding: 26,805,270
Previous closing price: $2.27
Market capitalization: $60 million

Disclaimer (emphasis added by me):

IMPORTANT NOTICE AND DISCLAIMER: This stock profile should be viewed as a paid advertisement. The BioScience Report is published by Kylne Ltd. In an effort to enhance public awareness of Cantabio Pharmaceuticals Inc. (“CTBO”) and its securities through the distribution of this advertisement, Ikon Media has provided the publisher with a weekly budget of approximately $150,000 to cover the costs associated with creating, printing and distribution of this advertisement. The publisher will retain any excess sums after expenses as its compensation. The publisher has not undertaken to determine if Ikon Media is, or intends to be in the future, directly or indirectly, a CTBO shareholder as it has no meaningful way to verify such facts. Readers should take this into consideration in evaluating bias. The name Cooper Stevens is a pseudonym for the editor who was paid $5,000 for his/her contributions to the report. If successful, this advertisement will increase investor and market awareness, which may result in increased numbers of shareholders owning and trading the common stock of CTBO, increased trading volumes, and possibly increased share price of CTBO’s common stock. This publication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. This publication, its publisher, and its editor do not purport to provide a complete analysis of any company’s financial position. The publisher and editor are not, and do not purport to be, broker-dealers or registered investment advisors. This publication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC filings. Investing in securities, particularly micro cap securities such as CTBO, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This publication is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the publisher cannot guarantee the accuracy or completeness of the information. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured company and/or industry. The publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company’s products and services, the ultimate degree of success in the company’s gaming apps in the near term and long term, etc. The BioScience Report is the publisher’s trademark. All other trademarks used in this publication are the property of their respective trademark holders. The publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the publisher to any rights in any third- party trademarks.

Copy of pump landing page (PDF)

Disclaimer. I have no position in any stock mentioned above. I have no relationship with any parties mentioned above. This blog has a terms of use that is incorporated by reference into this post; you can find all my disclaimers and disclosures there as well.

2 thoughts on “Cantabio Pharmaceuticals $CTBO promoted on purported Alzheimer’s cure”

  1. I bought in to CTBO on Thursday 6/2/16, at about $3.00/share, using a significant amount of retirement money. I would be proud to be an investor in a Company that is fighting Alzheimers and Parkinson diseases. However, I am a bit shaken by the pump and dump activity, having seem my investment increase in value to $3.59 (about a 20% gain) within a week, only to have it plummet to an interday low of about $1.54 on Monday 6/13/16. As of Monday 7/4/16, it is at $2.32. Could someone give me input on how to best approach my investment?

    1. Very, very few pump and dump companies ever achieve success and in the few times that has happened that was many years after initial investors experienced large losses on the initial pump and dump (Jimmy Choo is the only such company I am aware of). I am not aware of any medical company that was a big pump and dump that eventually achieved success. With an early stage pharma or biotech company the one thing the company needs is tens of millions of dollars in investments from people that believe in the company. CTBO insiders or large investors are the ones paying for the pump and dump so that tells you how much they believe in the company. With a market cap of $62 million and total assets of only $100,000 CTBO stands no chance in hell of ever succeeding for its current investors. I am 99.99% sure that investors in the company will suffer losses in excess of 90% over the next 2 to 5 years (and likely sooner).

      See their most recent 10-Q: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11268798

Leave a Reply

Your email address will not be published.

Please complete the formula below to prove that you are human * Time limit is exhausted. Please reload CAPTCHA.

This site uses Akismet to reduce spam. Learn how your comment data is processed.